Fig. 7

The effects of chronic systemic application of pentoxifylline (PTX, a cytokine blocker, 30 mg/kg, IP) for 5 weeks on the in situ ROS (n = 3 for each group, a–d), ROS level (n = 6–7 for each group, f), protein expression of TNFα in the PVN (n = 3–4 for each group, g) and TNFα content in plasma (n = 6–7 for each group, e). The values are mean ± SD; *p < 0.05 versus Control; ^#p < 0.05 versus OH